Journal
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Volume 316, Issue 3, Pages 1346-1350Publisher
AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
DOI: 10.1124/jpet.105.091975
Keywords
-
Categories
Funding
- NIDDK NIH HHS [P50 DK064236, R01DK049688, P50DK064236, R01 DK049688] Funding Source: Medline
Ask authors/readers for more resources
Prostaglandins (PGs) are involved in several major signaling pathways. Their effects are terminated when they are transported across cell membranes and oxidized intracellularly. The transport step of PG metabolism is carried out by the prostaglandin transporter (PGT). Inhibition of PGT would therefore be expected to change local or circulating concentrations of prostaglandins, and thus their biological effects. To develop PGT-specific inhibitors with high affinity, we designed a library of triazine compounds and screened 1842 small molecules by using Madin-Darby canine kidney cells stably expressing rat PGT. We found several effective PGT inhibitors. Among them, the most potent inhibitor had a K-i of 3.7 +/- 0.2 mu M. These inhibitors allowed us to isolate the efflux process of PGE(2) and to demonstrate that PGT does not transport PGE(2) outwardly under physiological conditions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available